These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16442619)

  • 21. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
    Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
    Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH; Tang JL; Chen RL; Li CC; Lee CP
    Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides.
    Szczylik C; Skórski T; Malaguarnera L; Hetman J; Chen ST; Calabretta B
    Folia Histochem Cytobiol; 1996; 34(3-4):129-34. PubMed ID: 8967957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.
    Tokunaga M; Ezoe S; Tanaka H; Satoh Y; Fukushima K; Matsui K; Shibata M; Tanimura A; Oritani K; Matsumura I; Kanakura Y
    J Biol Chem; 2010 Oct; 285(41):31774-82. PubMed ID: 20663870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. JAK the trigger.
    Mahon FX
    Oncogene; 2005 Nov; 24(48):7125-6. PubMed ID: 16007127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipocalin-2 is associated with modulation of disease phenotype in a patient with concurrent JAK2-V617F and BCR-ABL mutation.
    Nadarajan VS; Ang CH; Bee PC
    Eur J Haematol; 2012 Feb; 88(2):175-8. PubMed ID: 21950422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.
    Mc Lornan DP; Percy MJ; Jones AV; Cross NC; Mc Mullin MF
    Haematologica; 2005 Dec; 90(12):1696-7. PubMed ID: 16330446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of the JAK2 V617F mutation on PRV-1 expression.
    Mnjoyan Z; Yoon D; Li J; Delhommeau F; Afshar-Kharghan V
    Haematologica; 2006 Mar; 91(3):411-2. PubMed ID: 16503546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders.
    Kiladjian JJ; Elkassar N; Cassinat B; Hetet G; Giraudier S; Balitrand N; Conejero C; Briere J; Fenaux P; Chomienne C; Grandchamp B
    Leukemia; 2006 Jun; 20(6):1181-3. PubMed ID: 16598303
    [No Abstract]   [Full Text] [Related]  

  • 30. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.
    McClure R; Mai M; Lasho T
    Leukemia; 2006 Jan; 20(1):168-71. PubMed ID: 16270039
    [No Abstract]   [Full Text] [Related]  

  • 31. Insights into JAK2-V617F mutation in CML.
    Büsche G; Hussein K; Bock O; Kreipe H
    Lancet Oncol; 2007 Oct; 8(10):863-4. PubMed ID: 17913656
    [No Abstract]   [Full Text] [Related]  

  • 32. Absence of JAK2 V617F mutation in gastric cancers.
    Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
    Acta Oncol; 2006; 45(2):222-3. PubMed ID: 16546874
    [No Abstract]   [Full Text] [Related]  

  • 33. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression.
    Sengupta A; Banerjee D; Chandra S; Banerji SK; Ghosh R; Roy R; Banerjee S
    Leukemia; 2007 May; 21(5):949-55. PubMed ID: 17361218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia.
    Sulong S; Case M; Minto L; Wilkins B; Hall A; Irving J
    Br J Haematol; 2005 Sep; 130(6):964-5. PubMed ID: 16156866
    [No Abstract]   [Full Text] [Related]  

  • 35. Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.
    Yue Y; Wei W; Guo Y; Wang F; Dong W; Liu Y; Lin Y; Cao Y; Gu W
    Am J Case Rep; 2020 Oct; 21():e925151. PubMed ID: 33021971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insights into JAK2-V617F mutation in CML.
    Bocchia M; Vannucchi AM; Gozzetti A; Guglielmelli P; Poli G; Crupi R; Defina M; Bosi A; Francesco L
    Lancet Oncol; 2007 Oct; 8(10):864-6. PubMed ID: 17913657
    [No Abstract]   [Full Text] [Related]  

  • 37. Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia.
    Inami M; Yamaguchi H; Hasegawa S; Mitamura Y; Kosaka F; Kobayashi A; Kimura S; Dan K; Inokuchi K
    Leukemia; 2008 Jan; 22(1):216. PubMed ID: 17851549
    [No Abstract]   [Full Text] [Related]  

  • 38. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.
    Steensma DP
    J Mol Diagn; 2006 Sep; 8(4):397-411; quiz 526. PubMed ID: 16931578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas.
    Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
    Leuk Lymphoma; 2006 Feb; 47(2):313-4. PubMed ID: 16321863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.
    Jamieson CH; Gotlib J; Durocher JA; Chao MP; Mariappan MR; Lay M; Jones C; Zehnder JL; Lilleberg SL; Weissman IL
    Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6224-9. PubMed ID: 16603627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.